Immunotherapy duo shows promise against brain metastases in melanoma
NCT ID NCT02374242
First seen Jan 05, 2026 · Last updated Apr 28, 2026 · Updated 13 times
Summary
This study tests whether the immunotherapy drug nivolumab, alone or combined with ipilimumab, can shrink melanoma tumors that have spread to the brain. About 76 adults with stage IV melanoma and at least one brain metastasis will receive one of the two treatments. The main goal is to see how many patients have their brain tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Melanoma Institute Australia
Wollstonecraft, New South Wales, 2065, Australia
-
Peter MacCallum Cancer Centre
East Melbourne, Victoria, 3002, Australia
-
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
-
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
Conditions
Explore the condition pages connected to this study.